Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
Regeneron (NASDAQ: REGN) will report its Q2 2026 financial and operating results on Thursday, July 30, 2026, before U.S. markets open.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Regeneron (NASDAQ: REGN) will report its Q2 2026 financial and operating results on Thursday, July 30, 2026, before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time, with replay and transcript available for at least 30 days.
Details
News Market Reaction – REGN
On Jun 26, the first trading day after this news, REGN closed 2.06% above the previous close.
Data tracked by StockTitan Argus for the Jun 26 session.
Key Figures
- Earnings release date
- July 30, 2026
- Second quarter 2026 results to be reported before U.S. markets open
- Conference call time
- 8:30 AM Eastern Time
- Q2 2026 results conference call and webcast start time
- Replay availability
- 30 days
- Replay and transcript archived on company website for at least 30 days
Previous Conferences,earnings date Reports
-
Set timing for first quarter 2026 results and investor conference call.
-
Announced fourth quarter and full year 2025 results release and webcast schedule.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TARRYTOWN, N.Y., June 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its second quarter 2026 financial and operating results on Thursday, July 30, 2026, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day.
Conference Call Information
Participants may access the conference call live via webcast on the ’Investors and Media’ page of Regeneron’s website at https://investor.regeneron.com. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay and transcript of the conference call and webcast will be archived on the Company’s website for at least 30 days.
About Regeneron
Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visit www.Regeneron.com or follow Regeneron on LinkedIn, Instagram, Facebook or X.
| Contact Information: | |
| Investor Relations | Corporate Communications |
| Ryan Crowe | Christina Chan |
| 914.847.8790 | 914.847.8827 |
| ryan.crowe@regeneron.com | christina.chan@regeneron.com |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.